Diabetech - Diabetes Tech, Research, News

Beta Bionics is bringing its AID technology to a new patch pump format with the FDA-cleared Mint, expected to launch in Q1 2027. Mike Mensinger, Chief Product Officer at Beta Bionics breaks down how Mint’s two-part design works, from its reusable controller, to a Mint site and smartphone app demo. Mensinger shares what’s changing with the iLet, including the upcoming 3D Intelligence algorithm and planned Eversense 365 i...

Trio version 1.0 is here! This is the largest system update to date for the open-source automated insulin delivery (AID) system. The latest release adds new pump and CGM integrations, a redesigned app, customizable alerts, glucose forecasts, and new features like Quick Picks. This episode explores how Trio’s open-source approach differs from commercial AID systems and how users can customize the system around their diabetes m...

Your pump and CGM lose connection in the pool, and it comes down to centimeters. I sat down with Dr. Michael Hughes, an endocrinologist at Emory University, to break down his research on swimming with automated insulin delivery (AID). His team found the connection held at 100% at 10 cm, dropped to about half at 13 cm, and hit 0% by 17 cm, so where you place your pod and CGM matters a lot for swimming with type 1 diabetes. We also c...

Are you getting the most out of your automated insulin delivery system, or are you still managing it like a traditional insulin pump? Gary Scheiner, CDCES, and I break down 10 ways to optimize your AID system, from fine-tuning pump settings and knowing when to bolus to treating lows and timing insulin more effectively. We also cover how to trust the algorithm, use advanced pump features for exercise and meals, rotate infusion sites...

Abbott's VP of Technical Operations and Senior Medical Director break down the new Libre Duo sensor, the first continuous glucose ketone monitor. We discuss the growing need for more ketone data, how ketone alerts will appear in the existing Libre app, and why the company designed the experience to minimize alert and information fatigue. The conversation also covers Libre Duo’s compatibility with leading automated insulin del...

Eledon's CEO, Dr. David-Alexandre Gros, breaks down Tegoprubart, the company’s targeted immunosuppressant being studied alongside islet cell transplants for type 1 diabetes. The conversation covers the promising results seen so far, including insulin independence and improved A1C levels among trial participants, and why Tego could offer a different approach to protecting transplanted cells. The episode also explores what the ...

Ever wonder what insulin pump options exist outside the U.S.? Dr. Inge Van Boxelaer, a Belgian endocrinologist and founder of Diabetotech, joins us on the podcast and breaks down the European AID system landscape. We cover how MiniMed, Tandem, and Omnipod are performing across European markets, plus a deep dive into European systems like the Kaleido, mylife YpsoPump (with CamAPS FX and the upcoming Liberty algorithm), the Diabeloop...

Part two of this series continues the conversation about what a cure for type 1 diabetes could actually look like, from cell replacement and immune therapies to insulin innovation and advanced diabetes technology. The discussion explores islet cell transplants, stem cell-derived beta cells, immune suppression, gene-edited cells, and the challenges of making these approaches safer and more widely available. The expert panel also bre...

In this episode, I sit down with leading type 1 diabetes researchers and clinicians to break down the science behind prevention, delaying disease progression, and replacing insulin-producing beta cells. We explore promising therapies like teplizumab, ATG, and verapamil, along with the challenges of immunotherapy, beta cell replacement, and making these treatments accessible to more people. This conversation also tackles why we&rsqu...

When your CGM fails, your pump dies, or you're caught in a situation without access to your tech, do you know what to do? Gary Scheiner and I break down the "back to basics" skills every T1D needs to know from manual carb counting to calculating correction doses without a pump, to safely transitioning from a pump to MDI (and back again). We also cover what belongs in your diabetes emergency go-bag and how to best manage your care i...

A cure for type 1 diabetes has always felt like a distant idea, but for Patti Columbe, it's now her reality. After living with type 1 for 40 years, Patti shares her journey as a participant of the Vertex VX-880 clinical trial, where a lab-grown islet cell transplant has left her insulin-free and functionally cured. She opens up about the emotional challenges of adapting to life without diabetes and why she believes hope is finally ...

MiniMed’s new tubed insulin pump is finally here, and early users are beginning to share what life with the new insulin pump is really like. Our guests discuss using the system, the transition from previous pumps, what surprised them most, and how the smaller, app-controlled pump has impacted their day-to-day. The conversation also explores MiniMed's Meal Detection technology, how the algorithm handles missed or underestimate...

Greg Peterson has lived with type 1 diabetes for nearly 70 years and used an implantable insulin pump for more than two decades, even traveling from the U.S. to France to maintain it after the technology was discontinued. He shares how the implantable pump worked, how it dramatically improved his quality of life, and the profound impact it had on managing highs and lows as well as his relationships with loved ones. Two companies ar...

I sat down with diabetes technology expert, and pharmacist, Diana Isaacs to compare every AID pump currently available in the Unites States. We dive into how each system works, who it's best suited for, and the features that truly set them apart; from Omnipod 5's tubeless form factor and Sequel's twiist DIY roots to Tandem's Control-IQ+ algorithm, the screenless MiniMed Flex, and the ease of Beta Bionics iLet. We discuss real-world...

Gary Scheiner, CDCES, and I break down why carb counting is one of the trickiest parts of managing type 1 diabetes, and why getting it "close enough" is often more realistic than getting it perfect. We dive into how fat, protein, fiber, and alcohol each affect blood sugar differently, plus why insulin timing matters just as much as the dose. Gary shares practical estimation strategies like the hand and fist method, carb factors, an...

ADA 2026 Scientific Sessions brought a wave of exciting diabetes technology announcements, and Endo Dr. David Ahn and I dig into all of it in a live recording of the podcast! From a hands-on look at the new MiniMed Flex to updates from Tandem, Omnipod, twiist, and the open-source community, our discussion explores how these innovations could shape the future of diabetes care. We also dive into Abbott’s new dual glucose-ketone...

Commercial airline pilot John Roth shares how his diagnosis grounded him in 2015 and forced him to step away from the cockpit. Through years of advocacy, legal challenges, and advances in diabetes technology, John helped pave the way for pilots with type 1 diabetes to regain their right to fly. The conversation explores the emotional toll of losing a passion, the role CGMs played in changing FAA policy, and the strict medical requi...

I sat down with MiniMed's CTO to explore the new app-controlled pump, the MiniMed Flex and walk through its redesigned app ecosystem. We also discussed the next-generation Vivera algorithm, designed to reduce or potentially eliminate the need for meal boluses while improving time in range for users. And in a surprise reveal, MiniMed gave us an early look at the upcoming tubeless patch pump called "MiniMed Fit", sharing details abou...

Katie Beth Hand, patient 9 in the Eledon trial, received an islet cell transplant in January 2026. She is now living a "functionally cured" life, but every 21 days she requires a transfusion of an immunosuppressant called Tegoprubart which stops her body from attacking the newly implanted islet cells. In this conversation, we get into how the trial works, what it feels like to stop taking insulin after years of type 1 diabetes, and...